Oneness Biotech Co., Ltd. receives a Korean patent titled "TOPICAL FORMULATION FOR PROMOTING WOUND HEALING" on Fespixon cream (Research code: ON101).
· Issued by Oneness Biotech Co., Ltd.
Close
Today's Information
Provided by: ONENESS BIOTECH CO., LTD.
SEQ_NO
1
Date of announcement
2022/02/22
Time of announcement
17:52:33
Subject
Oneness Biotech Co., Ltd. receives a Korean patent
titled "TOPICAL FORMULATION FOR PROMOTING WOUND HEALING"
on Fespixon cream (Research code: ON101).
Date of events
2022/02/22
To which item it meets
paragraph 53
Statement
1.Date of occurrence of the event:2022/02/22
2.Company name:ONENESS BIOTECH CO., LTD.
3.Relationship to the Company (please enter "head office" or
"subsidiaries"):head office
4.Reciprocal shareholding ratios:NA
5.Cause of occurrence:The Company has been informed by the patent agency
that a Korean patent titled "TOPICAL FORMULATION FOR PROMOTING WOUND
HEALING" has been granted on the new drug Fespixon cream (Research
code: ON101) under the patent number 10-2362362.
6.Countermeasures:None
7.Any other matters that need to be specified:
(1)The new drug, Fespixon cream has been granted many international
patents. The development of new drugs is lengthy so many new drugs
are faced with expiring patent protection shortly after their market
approval, which results in loss of market exclusivity. The Company has
filed a new patent for the topical formulation of Fespixon cream with
innovative and efficacious scientific data and has been granted such
patent in the U.S., the largest market in February 2021, and
subsequently also granted in Russia, Mexico, Taiwan and Korea.
(2)The patent of the topical formulation of Fespixon new drug has been
filed in major countries or regions of the global market. The granted
patent term remains valid till 2037-2038. Extension of the patent term
can be applied for up to 5 years after the product is approved to be
marketed.
(3)During the term of the granted patent, Fespixon cream will be protected
against any generic competition.
